Filing Flows › Autolus Therapeutics (AUTL) › Q1 2026
Autolus Therapeutics (AUTL) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
Autolus Therapeutics (AUTL) reported revenue of $26.2M for the first quarter 2026 (Q1 2026), +192% from a year earlier and +8% from the quarter before. Operating margin was -227.0%, net loss $71.6M (273.1% of revenue).
Autolus Therapeutics, Q1 2026: revenue $26.2M (+192% year over year), operating margin -227.0%, net loss $71.6M, operating cash flow −$65.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $26.2M | +8% | +192% |
| Operating profit | −$59.5M | — | — |
| Net earnings | −$71.6M | — | — |
| Operating cash flow | −$65.3M | — | — |
What changed
Revenue was $26.2M in Q1 2026, up 192% year over year and up 8% from the previous quarter.
Operating costs exceeded revenue by $59.5M, an operating margin of -227.0%. Total costs grew 16% against revenue growth of 192%. The fastest-growing cost line was Cost of revenue (+37%). The quarter ended with a net loss of $71.6M, narrower than the previous quarter's $90.3M loss.
Operating cash flow was −$65.3M. Non-cash charges added back $2.2M of depreciation and amortization and $3.6M of share-based compensation. Capital expenditures of $2.7M exceeded it, leaving free cash flow of −$68.0M.
Questions
What was Autolus Therapeutics' revenue in the first quarter 2026?
Autolus Therapeutics (AUTL) reported revenue of $26.2M for the first quarter 2026 (Q1 2026), +192% from a year earlier and +8% from the quarter before.
Was Autolus Therapeutics profitable in the first quarter 2026?
Operating loss was $59.5M (-227.0% of revenue) and net loss $71.6M.